Projected Income Statement: ARS Pharmaceuticals, Inc.

Forecast Balance Sheet: ARS Pharmaceuticals, Inc.

Forecast Balance Sheet - ARS Pharmaceuticals, Inc.
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt - -274 -228 - - - - -
Change - - 16.79% - - - - -
Announcement Date 10/6/22 3/23/23 3/21/24 3/20/25 3/9/26 - - -
Estimates

Cash Flow Forecast: ARS Pharmaceuticals, Inc.

Fiscal Period: December 2022 2024 2025 2026 2027 2028
CAPEX 1 0.199 0.563 0.339 - - -
Change - - -39.79% -100% - -
Free Cash Flow (FCF) 1 - 12.98 -171.2 -195 -47.52 21.6
Change - - -1,418.48% -13.9% 75.63% 145.45%
Announcement Date 3/23/23 3/20/25 3/9/26 - - -
1USD in Million
Estimates

Forecast Financial Ratios: ARS Pharmaceuticals, Inc.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

        
EBITDA Margin (%) - - - - - - - -
EBIT Margin (%) - -2,698.78% -225,066.67% -3.46% -212.92% -153.25% -41.7% -6.34%
EBT Margin (%) - -2,635.41% -181,216.67% 9.29% -203.35% -157.17% -46.57% -6.28%
Net margin (%) - -2,635.41% -181,216.67% 8.97% -203.25% -156.19% -48.34% -5.5%
FCF margin (%) - - - 14.57% -203.14% -161.9% -28.72% 9.15%
FCF / Net Income (%) - - - 162.35% 99.95% 103.65% 59.42% -166.58%

Profitability

        
ROA -27.68% -12.56% -16.4% -0.66% -33.04% - - -
ROE -77.93% -21.84% -21.59% 3.28% -92.33% - - -

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) - 15.12% - 0.63% 0.4% - - -
CAPEX / EBITDA (%) - - - - - - - -
CAPEX / FCF (%) - - - 4.34% -0.2% - - -

Items per share

        
Cash flow per share 1 - - - - - - - -
Change - - - - - - - -
Dividend per Share 1 - - - - - - - -
Change - - - - - - - -
Book Value Per Share 1 - - - - - - - -
Change - - - - - - - -
EPS 1 -0.83 -0.87 -0.57 0.08 -1.74 -1.888 -0.7775 -0.11
Change - -4.82% 34.48% 114.04% -2,275% -8.48% 58.81% 85.85%
Nbr of stocks (in thousands) - 93,770 95,997 97,185 98,849 100,528 100,528 100,528
Announcement Date 10/6/22 3/23/23 3/21/24 3/20/25 3/9/26 - - -
1USD
Estimates
2026 *2027 *
P/E -1.78x -4.32x
PBR - -
EV / Sales 2.8x 2.04x
Yield - -

EPS & Dividend

EPS & Dividend - ARS Pharmaceuticals, Inc.


Y-o-Y evolution of P/E

Valuation ratios - P/E - ARS Pharmaceuticals, Inc.
 
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - ARS Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.360USD
Average target price
17.00USD
Spread / Average Target
+405.95%
  1. Stock Market
  2. Stocks
  3. SPRY Stock
  4. Financials ARS Pharmaceuticals, Inc.